Business
Dr. Paul Carney Joins Biotica Pharmaceuticals as Neurologist Consultant and Scientific Advisor
Dr. Paul Carney Joins Biotica Pharmaceuticals as Neurologist Consultant and Scientific Advisor.
About this update from Cardiac Biotech Solutions Inc.
[{"type":"text","content":"Sarasota, FL, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Biotica Pharmaceuticals Inc. (Biotica), an early-stage biotech engaging in the discovery, development, and commercialization of cannabinoid-based medicines for Neuropathic Pain, Cancer, Epilepsy, Autism, Alzheimer's, Parkinson, Esophagitis, and Immune Enhancement, announces today that it has selected Paul R. Carney, M.D. as its Neurologist Consultant and Scientific Advisor effective December 11, 2017. Dr. Carney through his years of research and clinical experience will lead Biotica’s clinical programs.Dr. Carney has over 20 years of basic translational and clinical research experience in neurological disorders. He is currently Professor and Director for Pediatric Neurosciences at the University of North Carolina at Chapel Hill. Dr. Carney a former Professor at the University of Florida College of Medicine, recently lead the Florida Department of Health sponsored cannabidiol research program. Over the past 20 years, his research has spanned translational basic and clinical research, with a major focus on the development of more effective treatments and diagnostics for epilepsy, cognitive and developmental disorders, and autism spectrum disorders.Dr. Carney will work closely with Biotica leadership in advancing the research and development objective of the Company. He will be instrumental in supporting the growth of neural disease division at Biotica, and provide strategic direction in developing pre-clinical phase and both clinical phase1 and 2 programs for testing the safety and efficacy of lead drug candidates. He will also advise on cannabinoid regulatory aspects and product pipeline development, and explore avenues for academic-industry collaborations. “We are quite excited to have Paul as our senior scientific advisor. His addition will be huge leap in pushing our drug candidates into the clinical phases” said Sam Talari, Chairman, Biotica Pharmaceuticals.Biotica Pharma is positioning to be a world-class research and development facility in endocannabinoid drug development. Biotica plans to set-up a state-of-the-art research and development lab to enhance the BPRx platform and rapidly expand its research capabilities. Biotica's research includes specific programs for Alzheimer's disease (BPRx060234), opioid overdose treatment (BPRx060314), eosinophilic esopha...